[The polypill: optimal strategy for reduction of cardiovascular disease].
Treating all persons above 55 years of age with a polypill for primary and secondary cardiovascular-disease prevention may reduce cardiovascular events by more than 80%. This strategy is expected to be cost-effective and the associated risk of side effects is estimated to be low.